Impact of Ischemia and Preservation Times on Survival in Transplant Recipients From After Circulatory Death Donors

Transplant Proc. 2023 Dec;55(10):2256-2258. doi: 10.1016/j.transproceed.2023.08.033. Epub 2023 Oct 8.

Abstract

Background: The limitation of ischemia times, which damages the organs and impacts transplant outcomes, is a drawback of controlled donation after circulatory death.

Methods: The aim of the study was to analyze the influence of preservation and ischemia times on overall survival and both censured graft survival and overall graft survival. This was an observational and retrospective study of patients undergoing liver transplantation with grafts from controlled donation after circulatory death between November 2013 and November 2022.

Results: Sixty-five patients were included in the study. Twenty percent (12 patients) developed early graft dysfunction according to Olthoff's classification, and 7 patients (11.6%) scored ≥7 points according to the Model for Early Allograft Function Scoring scale. Five patients (7.6%) met the criteria for primary graft failure. The retransplantation rate was 9.2% (6 cases). Fifty patients (76.9%) remained alive, and 15 patients (23.1%) died. When analyzing overall survival based on the main preservation and ischemia times, we observed that the best results occurred in the group with a functional warm ischemia time <12 minutes, with a survival rate at 1, 3, and 5 years of 95.8%, 87.1%, and 87.1%, respectively (P = .043). Regarding the analysis of censured graft survival based on the main preservation and ischemia times, we found that the worst results occurred in the group with a cold ischemia time ≥6 hours, with a survival rate of around 48% at 3 and 5 years (P = .047).

Conclusions: High-risk patients have lower overall and graft survival in the short and long term in grafts from controlled donation after circulatory death.

Publication types

  • Observational Study

MeSH terms

  • Death
  • Graft Survival
  • Humans
  • Ischemia / etiology
  • Retrospective Studies
  • Tissue Donors
  • Tissue and Organ Procurement*
  • Transplant Recipients*
  • Warm Ischemia / adverse effects